Hypertension, type 2 diabetes, diabetic nephropathy
Conditions
Interventions
Telmisartan group: Start with once-daily dosing of telmisartan 20 mg daily for 24 weeks, and dosage may be modulated accroding to the clinical parameters (telmisartan 20-80 mg daily). Target blood pre
Sponsors
Department of Cardiorenal Medicine, Yokohama City University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetes. 2. Mild-to-moderate hypertension (clinic systolic BP more than 130 mmHg, clinic diastolic BP more than 80 mmHg or on antihypertensive drugs). 3. Urinary protein excretion more than 0.3 g daily, or urinary protein concentartion more than 300 mg/gram urinary creatinine on spot urine examination.
Exclusion criteria
Exclusion criteria: 1. Pregnant women, or women suspected of being pregnant 2. Hyperkalemia 3. History of hypersensitivity to Telmisartan or Irbesartan 4. Severe liver disorder, or severe biliary atresia. 5. Severe hypertension (clinic BP more than 180/100 mmHg).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Clinic blood pressure. 2. Ambulatory blood pressure monitoring: mean blood pressure, day-night variation, short-term blood pressure/heart rate variability, LF/HF. 3. Renal function: eGFR, urinary protein/albuminon excretion, urinary urea nitrogen, urinary type 4 collagen. 4. Glucose metabolism: fasting blood glucose, fasting IRI, HOMA-IR. 5. Lipid metabolism: total cholesterol, LDL, HDL, TG. 6. Renin-angiotensin system, inflammatory and oxidative stress markers: PRA, Urinary angiotensinigen, HMW-adiponectin, AGE, MDA-LDA, ADMA, cathecholamine. 7. Vascular function: ABI/baPWV. | — |
Countries
Japan
Contacts
Public ContactKazukai Uchino
Yokohama City University Graduate School of Medicine Department of Medical Science
Outcome results
None listed